Leslie Fang, MD
Nephrology · Boston, MANPI 1558351734
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $326,304 of the $387,680 with a category attached, or 84.2%. Strategic Dentistry LLC accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $181,848 and has fallen 100.0% since, to $5 in 2024. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $6922.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Strategic Dentistry LLC$388K
- Travere Therapeutics, Inc.$5
What the payments were for
- Royalty or licence$14,4124%
- Consulting fees$37,29310%
- Speaking & faculty fees$326,30484%
- Travel & lodging$9,4982%
- Food & beverage$390%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Strategic Dentistry LLC | 54 | $387,675 |
| Travere Therapeutics, Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sedation Dentistry Guidebook Renewal$129
How this compares
$387,680 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $218,624 |
| JardianceEmpagliflozin | 61 | $65,581 |
| OzempicSemaglutide | 48 | $63,187 |
| TrulicityDulaglutide | 52 | $59,587 |
| Repatha SureclickEvolocumab | 81 | $59,424 |
| XareltoRivaroxaban | 45 | $51,529 |
| LinzessLinaclotide | 41 | $33,346 |
| MounjaroTirzepatide | 26 | $28,103 |
| EntrestoSacubitril/Valsartan | 25 | $23,485 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $18,081 |
| Dexlansoprazole DrDexlansoprazole | 43 | $15,579 |
| FarxigaDapagliflozin Propanediol | 13 | $13,600 |
| Olmesartan Medoxomil | 307 | $12,341 |
| MyrbetriqMirabegron | 12 | $11,821 |
| MultaqDronedarone Hcl | 13 | $8,748 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boston
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
- Andrew AllegrettiBoston$139K
- Ravi ThadhaniBoston$115K
- Meghan SiseBoston$113K
- Ronald PerroneBoston$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.